Skip to main content
Loading

Integrating Market Access Strategy in Preclinical Gene Therapy Development

18 Sep 2025
Commercializing Gene Therapy in 2025
  • The importance of aligning early stage development, CMC perspective to pave a path to win market access
  • The importance of aligning preclinical design with market access goals - considering urgent needs, patient populations, and payer expectations from the earliest stages
  • Early integration of target product profiles with regulatory and health economics insights helps guide decisions of delivery platforms, such as peptide-modified AAVS, to meet future reimbursement requirements
  •  Engaging stakeholders, clinicians, payers and advocacy groups - preclinically ensures clinical relevance and commercial viability of gene therapies before entering the clinic 
Industry Expert
Shengjiang Shawn Liu, President, CSO & CEO - Avirmax